ICCPP-GROUP
9.5.2023 13:08:32 CEST | Business Wire | Press release
With the global prevalence of disposable e-cigarettes, there are growing concerns about the environmental problems caused. As one of key influencers of electronic atomization technology companies, as well as the parent company of VOOPOO, ICCPP Group takes these problems seriously and its ODM+ business has creatively developed world’s 1st new dual environmentally-friendly disposable vape solutions, named "Cyclo" series, which combines the concept of detachable and biodegradable, ahead of the industry in advance to achieve user portability and recyclability, will be grandly unveiled at the Vaper Expo UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005592/en/
The "Cyclo" eco-friendly vape solutions of ICCPP ODM+ (Photo: Business Wire)
Patented PLA Material: The Key to Make Stable Biodegradability Reality The "Cyclo" series are made with our exclusive and patented PLA material, a biodegradable material that is made from starch raw materials proposed from corn, a renewable plant resources, and which can be degraded into carbon dioxide and water in 3-6 months after being recycled and landfilled in the soil, making it a more environmentally friendly material.
In addition, ICCPP has gone through thousands of trials and tests and created a unique internal structure and process to further enhance the stability of unique PLA material, making it maintain its initial strength after thousands of drop and impact tests, to greatly improve the stability and safety of PLA e-cigarette sticks, without destroying the original biodegradable advantages of the material.
Leadless and Modular Design: Making Detachability A Reality
ICCPP’s commitment to environmental sustainability goes much further than just material selection.
We have implemented a wide range of environmentally-friendly design features, including no-soldering lead-free design and pre-automated modular assembly. These design features mean that "Cyclo" vape solutions can be easily disassembled for recycling or disposal, minimizing the environmental impact of manufacturing and using processes.
Multiple Options for Atomization Coils: The Addition of Environmental Concepts
ICCPP’s commitment to environmental sustainability does not end with the product itself. We have also advanced atomization coil technology into "Cyclo" series, resulting in a longer lifespan, less material waste, and a more stable and pure taste for vapers.
The atomization coil technology in the "Cyclo" vape solutions includes the mesh coil technology and the Gene Tree ceramic coil technology. On one hand, our mesh coil technology combines different resistivity application scenarios with a unique multi-layer distribution structure to precisely control the power at a single point and precisely calculate the heat field coverage at a single point to so that the heat is evenly distributed, resulting in a stable, perfect and pure taste.
On the other hand, the Gene Tree ceramic coil technology uses the exclusive powder-free environmental-friendly technology process, nano-microcrystalline ceramic material fired at 3000°, and a multi-layer A+ grade oil guide and oil lock aperture structure to provide more stable and uniform heating. This unique combination of technologies ensures that "Cyclo" e-cigarettes solutions provide customers with more puffs, purer tastes, greater flavor consistency and a superior vaping experience, as well as less environmental concerns .
The Origin of "Cyclo": The Commitment of ICCPP to the Environment and Society
In view of these, we name the electronic cigarettes solutions "Cyclo", representing our dedication to creating a closed-loop, circular product cycle that is both environmentally-friendly and sustainable. Also,the slogan of “Cyclo” is “Cycle of all things", and it reflects our dedications and determination to promoting environmental sustainability in all areas of our business.
In conclusion, the "Cyclo" series of e-cigarettes are the perfect choice for those who want an environmentally-friendly and sustainable vaping experience. With biodegradable materials, recyclable design features, cutting-edge atomization coil technology, as well as our commitment to environmental responsibility, we invite you to join us in the journey towards a more sustainable future.
Of course, apart from “Cyclo” eco-friendly products, ICCPP ODM+ brings dozens of vapes including refillable pods and disposable pods for UK e-cigarette enthusiasts and industry experts that meet local market flavor and puff preferences and also obey local regulations. Welcome to E10 booth at NEC of Birmingham and we look forward to seeing you on May 12th-14th 2023.
1)About ICCPP ODM+:
ICCPP ODM+ is an innovative ODM strategic cooperation model created by ICCPP Group in 2022, which puts forward the business proposition of “branding first, product integrating technology and marketing”.
Through all-round innovations and breakthroughs in technology+, product+, flavor+, quality+, compliance+ and marketing+, ICCPP ODM+ provides more premium vape solutions and services for customers' brands, so as to bring a healthier and happier electronic atomization life to global consumers and to achieve long-term development of both customers' brands and ICCPP ODM.
2)About ICCPP Group:
ICCPP Group, the parent company of VOOPOO, is a comprehensive electronic atomization ecological group with the whole industrial chain layout. It is rapidly developing with a new business model of matrix, internationalization and platform, integrating technology R&D, product design, intelligent manufacturing, brand operation and supply chain management.
With 9 years of full industry chain layout and global localization, ICCPP's electronic atomization products and solutions have been applied in more than 70 countries worldwide, covering 100,000 offline outlets and more than 36 million consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005592/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
